Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03982004 · ClinicalTrials.gov registry record · Phase 1
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03982004 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 1 participants.
The verdict
NCT03982004, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this research study is to look at the safety and side effects of combining the drug pembrolizumab with imiquimod, GM-CSF, and cryotherapy to treat breast cancer that includes skin lesions.
Interventions
- DRUG Pembrolizumab
- DEVICE Epicutaneous cryoimmunotherapy
- DRUG Topical imiquimod
- OTHER Dermatologic Quality of Life Index
- OTHER Functional Assessment of Cancer Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2021-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03982004
The ClinicalTrials.gov registry entry for NCT03982004 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03982004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03982004 about?
NCT03982004 is a clinical study titled "Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer". The purpose of this research study is to look at the safety and side effects of combining the drug pembrolizumab with imiquimod, GM-CSF, and cryotherapy to treat breast cancer that includes skin lesions.
What is the current status of trial NCT03982004?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-09-14. Estimated completion is 2021-03-03.
What interventions are being tested in trial NCT03982004?
The interventions under investigation include: Pembrolizumab (DRUG), Epicutaneous cryoimmunotherapy (DEVICE), Topical imiquimod (DRUG), Dermatologic Quality of Life Index (OTHER), Functional Assessment of Cancer Therapy (OTHER).
Who is sponsoring clinical trial NCT03982004?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.